利索-全球专利检索

  1. Login
  2. Sign Up

Search Results

591 records (took 0.039 seconds)

    Pharmaceutical compositions
    32.
    发明授权
    Pharmaceutical compositions 有权

    公开(公告)号：US08957054B2

    公开(公告)日：2015-02-17

    申请号：US13544407

    申请日：2012-07-09

    Applicant: Fernand Labrie

    Inventor： Fernand Labrie

    IPC: A61K31/56 ,  A61K9/00 ,  A61K31/5685 ,  A61K31/453

    CPC classification number: A61K31/453 ,  A61K9/0014 ,  A61K9/0034 ,  A61K31/56 ,  A61K31/5685

    Abstract: Novel methods for treating or reducing the likelihood of acquiring symptoms or diseases due to the menopause, in postmenopausal women, particularly osteoporosis, vaginal atrophy and dryness, hypogonadism, diminished libido, skin atrophy, connective tissue disease, urinary incontinence, breast, endometrial, ovarian and uterine cancers, hot flashes, loss of muscle mass, insulin resistance, fatigue, loss of energy, aging, physical symptoms of menopause, in susceptible warm-blooded animals including humans involving administration of a sex steroid precursor are disclosed. Said method comprising novel ways of administering and dosing dehydroepiandrosterone (DHEA) in order to take advantage of positive androgenic effects in the vaginal layers lamina propia and/or the layer muscularis, without undesirably causing systemic estrogenic effects in order to avoid the risk of breast and uterine cancer. Pharmaceutical compositions for delivery of active ingredient(s) useful to the invention are also disclosed.

    ANDROGEN AND GONADOTROPIN TREATMENT IN FEMALES
    34.
    发明申请
    ANDROGEN AND GONADOTROPIN TREATMENT IN FEMALES 审中-公开
    安非他酮和金丝桃素处理

    公开(公告)号：US20140235540A1

    公开(公告)日：2014-08-21

    申请号：US14100202

    申请日：2013-12-09

    Applicant: Norbert Gleicher ,  David H. Barad ,  Dwyn V. Harben

    Inventor： Norbert Gleicher ,  David H. Barad ,  Dwyn V. Harben

    IPC: A61K38/24 ,  A61K31/5685

    CPC classification number: A61K38/24 ,  A61K31/568 ,  A61K31/5685 ,  A61K2300/00

    Abstract: A method of treating a human female with an androgen and a gonadotropin to improve at least one of the human female's infertility, reproductive outcomes and oocyte yield is disclosed. The method may include treating the female with an androgen and a gonadotropin in combination. The androgen may be administered for more than six weeks and the gonadotropin may be administered in a regular low dosage over a period of time longer than two weeks. The method may include inducing ovulation in the female by administering gonadotropins to stimulate ovulation and/or induce ovulation. The method may include multiple additional inductions of ovulation, each within 120 days of the previous induction of ovulation.

    Abstract translation: 公开了一种用雄激素和促性腺激素治疗人类女性以改善至少一种人类女性的不育症，生殖结果和卵母细胞产量的方法。 该方法可以包括用雄激素和促性腺激素组合治疗雌性。 雄激素可以施用六周以上，并且可以在超过两周的时间内以常规低剂量施用促性腺激素。 该方法可以包括通过施用促性腺激素来刺激排卵和/或诱导排卵来诱导雌性排卵。 该方法可以包括多次额外的排卵诱导，每次在先前诱导排卵后的120天内。

    Use of aromatase inhibitors for treatment of ectopic pregnancy
    36.
    发明授权
    Use of aromatase inhibitors for treatment of ectopic pregnancy 有权
    使用芳香酶抑制剂治疗异位妊娠

    公开(公告)号：US08685950B2

    公开(公告)日：2014-04-01

    申请号：US11664768

    申请日：2005-10-04

    Applicant: Mohamed F. M. Mitwally ,  Michael P. Diamond ,  Robert F. Casper

    Inventor： Mohamed F. M. Mitwally ,  Michael P. Diamond ,  Robert F. Casper

    IPC: A61K31/56

    CPC classification number: A61K31/4196 ,  A61K31/56 ,  A61K31/5685

    Abstract: Following a diagnosis of ectopic pregnancy, at least one aromatase inhibitor, is administered to a patient, either alone or in combination with other aromatase inhibitors or therapeutic agents or as an adjuvant to conservative surgical treatment, such as laparoscopy, to prevent the establishment and/or continuation of the ectopic pregnancy. In certain preferred embodiments, the aromatase inhibitor is administered in conjunction with methotrexate.

    Abstract translation: 诊断为异位妊娠后，将至少一种芳香酶抑制剂单独或与其它芳香酶抑制剂或治疗剂组合施用于患者，或作为保守手术治疗如腹腔镜检查的佐剂，以防止建立和/ 或继续宫外孕。 在某些优选的实施方案中，芳香酶抑制剂与甲氨蝶呤一起施用。

    USE OF ANDROGEN FOR DISEASE TREATMENT
    37.
    发明申请
    USE OF ANDROGEN FOR DISEASE TREATMENT 审中-公开
    使用治疗疾病的原因

    公开(公告)号：US20140088050A1

    公开(公告)日：2014-03-27

    申请号：US14035237

    申请日：2013-09-24

    Applicant: Edward M. Lichten

    Inventor： Edward M. Lichten

    IPC: A61K31/585 ,  A61K31/567 ,  A61K31/565 ,  A61K31/58 ,  A61K31/5685 ,  A61K31/568

    CPC classification number: A61K31/585 ,  A61K31/565 ,  A61K31/567 ,  A61K31/568 ,  A61K31/5685 ,  A61K31/58 ,  A61K2300/00

    Abstract: By lowering and then after raising the amount of SHBG in the body, an effective method for treatment of various diseases is achieved. First and seconds androgens, namely, anabolic steroids are used to both lower the SHBG and, thereafter raise the testosterone in the body until equilibrium between the SHBG and the second steroid, to normalize the FAI. Stanozolol is the preferred anabolic steroid used herein to lower the SHBG and testosterone is used to normalize the FAI.

    Abstract translation: 通过降低，然后在体内增加SHBG的量后，可以实现治疗各种疾病的有效方法。 第一和第二代雄激素，即合成代谢类固醇都用于降低SHBG，然后将体内的睾酮升高至SHBG和第二类固醇之间的平衡，以使FAI正常化。 在本文中使用的优选的合成代谢类固醇是降低SHBG，而睾酮用于使FAI正常化。

    Enhancement of urogenital function
    40.
    发明授权
    Enhancement of urogenital function 失效
    增强泌尿生殖功能

    公开(公告)号：US08513306B2

    公开(公告)日：2013-08-20

    申请号：US12978312

    申请日：2010-12-23

    Applicant: Robert W. Hander

    Inventor： Robert W. Hander

    IPC: A01N33/02

    CPC classification number: A61K31/205 ,  A61K31/13 ,  A61K31/198 ,  A61K31/519 ,  A61K31/5685 ,  A61K45/06 ,  A61K2300/00

    Abstract: A method of treating nocturia in a human individual includes administering dosages of creatine to the individual; and reducing the dosages of creatine to the individual responsive to an increase in difficulty of the individual to initiate urination. Another example method includes reducing the dosages of creatine to the individual responsive to an increase in nocturnal urination frequency of the individual. A dosing system includes doses of creatine for treating nocturia in a human individual and is configured for reduced doses for administration in response to an increase in one or more nocturia symptoms. Various other methods as well as compositions, systems, etc., are also disclosed.

    Abstract translation: 治疗人类夜尿症的方法包括向个体施用肌酸的剂量; 并且根据个体开始排尿的难度增加，减少对个体肌酸的剂量。 另一个示例性方法包括根据个体的夜间排尿频率的增加来减少对个体肌酸的剂量。 给药系统包括用于治疗人类个体的夜尿症的肌酸剂量，并且被配置为响应于一种或多种夜尿症状的增加而减少的给药剂量。 还公开了各种其它方法以及组合物，系统等。

Patent Agency Ranking